REPLIGEN CORP Unrealized Gain (Loss) on Derivatives
REPLIGEN CORP (RGEN) reported Unrealized Gain (Loss) on Derivatives of -$8.71 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2025-08-07
- REPLIGEN CORP unrealized gain (loss) on derivatives for the quarter ending 2025-06-30 was -$486.00K.
- REPLIGEN CORP unrealized gain (loss) on derivatives for the quarter ending 2025-03-31 was -$8.22M.
- REPLIGEN CORP unrealized gain (loss) on derivatives for the quarter ending 2024-06-30 was $0.00.
- REPLIGEN CORP unrealized gain (loss) on derivatives for the quarter ending 2024-03-31 was $0.00.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month |
|---|---|---|
| 2025-06-30 | -$486.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$8.71M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$8.22M 10-Q · filed 2025-04-29 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |